Drug & intervention
entrectinib
RxCUI 2197862
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Clinical trials
13 shownStudy on the Mechanism of Acquired Resistance of EntrectinibNCT07199959 · 2025-01-15
RECRUITINGA Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)NCT04302025 · 2020-11-06
RECRUITINGReal-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLCNCT06694129 · 2024-12-01
NOT_YET_RECRUITINGA Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.NCT05834348 · 2023-06-23
COMPLETEDSMMART Adaptive Clinical Treatment (ACT) TrialNCT05238831 · 2023-01-30
WITHDRAWNA Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)NCT05170204 · 2022-11-01
ACTIVE_NOT_RECRUITINGA Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) MetastasesNCT04603807 · 2021-09-30
ACTIVE_NOT_RECRUITINGNeoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)NCT04551495 · 2021-01-14
UNKNOWNThe Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyNCT04591431 · 2020-10-07
UNKNOWNSerial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialNCT03878524 · 2020-04-01
TERMINATEDA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)NCT03178552 · 2017-09-22
ACTIVE_NOT_RECRUITINGStudy Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment OptionsNCT02650401 · 2016-05-03
ACTIVE_NOT_RECRUITINGBasket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)NCT02568267 · 2015-11-19
ACTIVE_NOT_RECRUITINGConditions being studied
Non-Small Cell Lung Cancer6Anatomic Stage IV Breast Cancer AJCC v82Breast Cancer2Non Small Cell Lung Cancer2Stage II Pancreatic Cancer AJCC v82Stage III Pancreatic Cancer AJCC v82Stage IV Pancreatic Cancer AJCC v82Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1Adult Solid Tumor1Advanced Breast Carcinoma1Advanced Malignant Solid Neoplasm1Advanced Ovarian Carcinoma1Advanced Pancreatic Carcinoma1Advanced Prostate Carcinoma1Advanced Sarcoma1Anatomic Stage III Breast Cancer AJCC v81Anemia1Ann Arbor Stage III Hodgkin Lymphoma1Ann Arbor Stage III Non-Hodgkin Lymphoma1Ann Arbor Stage IV Hodgkin Lymphoma1
Research locations
Leading sponsors
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.